NewsRoom Articles - BioMedWire (BMW)

MondaySep 28, 2026 2:00 pm

Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

Orthopedic practice is moving away from a model that manages knee pain until the joint fails, to early structural intervention - a shift that raises the bar for what a cartilage repair product has to deliver. Regentis' GelrinC is an acellular hydrogel implant designed to erode in a controlled, synchronized manner as surrounding cells regenerate hyaline-like cartilage, with Phase II data showing approximately 100% greater KOOS improvement than microfracture at two years. With CE Mark approval in Europe, pivotal U.S. trial enrollment targeted for completion by approximately year end 2026, and platform work extending toward moderate osteoarthritis, the company is…

MondaySep 28, 2026 10:00 am

Researchers in South Korea Identify New Protein That Controls Brain Cancer Growth

Glioblastoma is the deadliest form of brain cancer due to its aggressive growth rate. Most patients don’t survive for more than a year after diagnosis, and the disease quickly develops resistance to existing treatments. Scientists have been racing to find ways to treat this malignancy and prolong patient survival. Now, a team of researchers in South Korea have found a novel protein that acts as the switch regulating glioblastoma’s growth. The researchers also identified a compound that can turn off this switch, effectively slowing down the cancer’s growth and reducing the size of tumors. Doctor Han Tae-su, who led the…

FridaySep 25, 2026 9:45 am

Nanox’s Integrated Imaging Ecosystem: Expanding Access to 3D Imaging and Diagnostics

Roughly two-thirds of the world’s population lacks access to basic imaging technology, and the radiologist workforce gap is just as stark. Nanox brings together Nanox.ARC, Nanox.AI, Nanox.CLOUD, Nanox.MARKETPLACE, USARAD Holdings and Nanox Health IT as part of its broader imaging ecosystem. Commercial activity is beginning to build, with second-quarter revenue of $4.2 million. Advanced medical imaging has transformed diagnosis, yet access to it remains remarkably uneven. Roughly two-thirds of the world’s population lacks access to basic imaging technology, a figure widely attributed to the World Health Organization, and the workforce gap is just as stark: an estimated 1.9 radiologists per…

ThursdaySep 24, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

The FDA IND approval marks a pivotal step for the company's lead compound, known as Lucid-MS. What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism. Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated. A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved…

ThursdaySep 24, 2026 10:00 am

Why Treating Cancer is So Complicated

Cancer care has evolved over the past decades and one would expect that the more the field evolves, the easier it would get to care for cancer patients. The reality is far more complex and it has become very complicated to provide cancer care. Several factors explain this complexity. The word cancer is a broad term and doesn’t refer to a single disease. There are so many types of cancer that one would be hard-pressed to give a quick answer as to how many cancer types exist. Each cancer is different from all other cancers even if many cancer types…

TuesdaySep 22, 2026 10:30 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

In the United States alone, close to one million people are living with MS, with a landmark study finding that figure was more than double what had previously been assumed. Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability. Quantum BioPharma's Lucid-MS candidate is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2. Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality…

TuesdaySep 22, 2026 10:00 am

Survey Finds That Insurance Doesn’t Shield Americans from Medical Debt

A nationwide survey conducted by the Commonwealth Fund has found that contrary to a common view that it is the uninsured that incur medical debt, the reality is that a sizeable fraction of adults in the U.S. with health insurance have medical debt. The survey data reveals that about 33% of Americans that have private health insurance have medical debt, and nearly 40% of this group revealed that they drained part or all of their savings so they could pay bills. This finding offers a sobering reality check: health insurance is failing to deliver on one of its key objectives…

MondaySep 21, 2026 10:30 am

Earth Science Tech Inc.’s (ETST) Uplist to OTCQB Venture Market Continues Series of Milestones in Fiscal 2027

Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that provides investors with a trusted trading environment The uplisting is one of several milestones the company has reported during the current financial year 2027, which began on April 1, 2026 The company reported its Q1 2027 financial results, marking a 3% growth in revenue with a 57% increase in net income The company also acquired Meduvo LLC and Zoolzy and held its annual meeting of shareholders Earth Science Tech (OTCQB: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, successfully uplisted to…

MondaySep 21, 2026 9:45 am

VERAXA Biotech AG (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company entered the NASDAQ market in June 2026 following its completed business combination with Voyager Acquisition Corp., giving VERAXA access to the U.S. public markets as it advances its development programs. BiTAC is designed as an “AND-gated” therapeutic approach in which two complementary components must engage the same cancer cell before the intended cytotoxic mechanism is activated. VERAXA has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches, including an in-vitro proof of concept for BiTAC-ADC announced in…

FridaySep 18, 2026 10:00 am

Bacterial Strains Influence Meningitis, Pneumonia Risks from Air Pollution, New Study Finds

A new study has found that the risk of people developing sepsis, meningitis or pneumonia as a result of exposure to air pollution is influenced by the specific bacterial strains that an individual carries within their microbiome. The study, whose findings were published in the journal Nature Microbiology on September 14 this year, was conducted by a joint team from the South African National Institute of Communicable Diseases, the Supercomputing Center in Barcelona, Spain, together with other collaborators. The researchers focused on Streptococcus pneumoniae, a bacterium that lives within the respiratory microbiome. It typically lives inside the throat and nose,…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Regentis Biomaterials and the Shift from Symptom Management to Structural Repair in Knee Cartilage Care

Researchers in South Korea Identify New Protein That Controls Brain Cancer Growth

Nanox’s Integrated Imaging Ecosystem: Expanding Access to 3D Imaging and Diagnostics

Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

Why Treating Cancer is So Complicated

Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

Survey Finds That Insurance Doesn’t Shield Americans from Medical Debt

Earth Science Tech Inc.’s (ETST) Uplist to OTCQB Venture Market Continues Series of Milestones in Fiscal 2027

VERAXA Biotech AG (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

Bacterial Strains Influence Meningitis, Pneumonia Risks from Air Pollution, New Study Finds

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search